DTXMF: AI 评分 51/100 — AI 分析 (4月 2026)

Deltex Medical Group plc specializes in oesophageal Doppler haemodynamic monitoring systems. Their TrueVue system is used in various surgeries and critical care settings to optimize patient fluid management and blood flow.

Key Facts: AI Score: 51/100 Sector: Healthcare

公司概况

概要：

Deltex Medical Group plc provides haemodynamic monitoring solutions, primarily through its TrueVue Doppler system, used in critical care and surgical settings. The company focuses on optimizing fluid management and blood flow in patients, operating within the competitive medical devices market, with a global presence in the UK, US, Spain, and Canada.

DTXMF是做什么的？

Deltex Medical Group plc, established in 2000 and headquartered in Chichester, UK, develops, manufactures, and markets haemodynamic monitoring systems. Its flagship product, the TrueVue oesophageal Doppler monitoring (ODM) system, provides real-time blood flow and fluid status measurements. This technology assists clinicians in optimizing fluid management during surgery and in critical care settings. The company's product line includes esophageal Doppler Probes, Loops, High Definition Impedance Cardiography, PressureWave, and the Deltex Medical Esophageal Doppler Simulator. These products are utilized in a range of medical procedures, including major abdominal, laparoscopic, and spinal surgeries, cardiac, trauma, and transplant procedures, as well as in the management of conditions like sepsis and post-operative acute kidney injury. Deltex Medical distributes its products in the United Kingdom, the United States, Spain, and Canada, as well as internationally. Deltex Medical's focus on precision fluid management positions it within the broader medical devices market, catering to the needs of hospitals and surgical centers seeking to improve patient outcomes and reduce complications related to fluid imbalances.

DTXMF的投资论点是什么？

Deltex Medical Group plc presents a focused investment opportunity within the haemodynamic monitoring sector. The company's TrueVue system addresses a critical need for precise fluid management in surgical and critical care settings. While the company's negative P/E ratio of -0.22 and profit margin of -72.2% indicate current challenges, the 63.3% gross margin suggests potential for profitability with increased sales and cost management. Growth catalysts include expanding adoption of TrueVue in the US market and potential partnerships with larger medical device companies. Key risks include competition from established players and the need for continued innovation to maintain market relevance. The company's beta of -2.55 suggests a low correlation with the overall market.

DTXMF在哪个行业运营？

Deltex Medical Group plc operates within the medical devices industry, specifically focusing on haemodynamic monitoring. The market is characterized by technological advancements and increasing demand for minimally invasive and precise monitoring solutions. Key trends include the growing adoption of advanced monitoring technologies in critical care and surgical settings, driven by the need to improve patient outcomes and reduce complications. The competitive landscape includes companies like ACRDF (Accuray Incorporated), BLMHF (Bellerophon Therapeutics Inc), DOCRF (Second Sight Medical Products Inc), FFLWF (Fluidigm Corporation), and PXMVF (Proximus NV), each offering various monitoring solutions. Deltex Medical differentiates itself through its unique oesophageal Doppler technology and focus on fluid management.

Medical - Devices

Healthcare

DTXMF有哪些增长机遇？

Expansion in the US Market: Deltex Medical has a significant opportunity to expand its presence in the US market. The US medical device market is one of the largest in the world, with a growing demand for advanced haemodynamic monitoring technologies. By increasing its sales and marketing efforts in the US, Deltex Medical can capitalize on this demand and drive revenue growth. This expansion could be accelerated through strategic partnerships with US-based distributors or healthcare providers. Timeline: Ongoing.
Strategic Partnerships and Acquisitions: Deltex Medical can pursue strategic partnerships or acquisitions to expand its product portfolio and market reach. Collaborating with complementary medical device companies or acquiring smaller players with innovative technologies can enhance Deltex Medical's competitive position and accelerate growth. These partnerships could provide access to new markets, technologies, or distribution channels. Timeline: Ongoing.
Product Innovation and Development: Continued investment in research and development is crucial for Deltex Medical to maintain its competitive edge. By developing new and improved haemodynamic monitoring technologies, the company can address unmet clinical needs and attract new customers. This includes exploring non-invasive monitoring solutions and integrating its technology with other medical devices. Timeline: Ongoing.
Adoption in Emerging Markets: Deltex Medical can explore opportunities to expand its presence in emerging markets, where there is a growing demand for advanced medical technologies. These markets often have less stringent regulatory requirements and lower competitive intensity, providing a favorable environment for growth. However, it is important to carefully assess the market dynamics and regulatory landscape before entering these markets. Timeline: Ongoing.
Integration with Electronic Health Records (EHR) Systems: Integrating Deltex Medical's haemodynamic monitoring data with EHR systems can enhance the value proposition for healthcare providers. This integration would allow clinicians to access real-time patient data and make more informed decisions. It would also streamline the workflow and reduce the risk of errors. Timeline: Ongoing.

Market capitalization of $0.18 billion indicates the company's current valuation in the market.
Negative P/E ratio of -0.22 reflects current unprofitability, suggesting potential for future earnings growth.
Gross margin of 63.3% demonstrates the company's ability to generate revenue above the cost of goods sold.
Beta of -2.55 indicates a negative correlation with the market, suggesting potential stability during market downturns.
The company operates internationally, with a presence in the UK, US, Spain, and Canada, providing geographic diversification.

DTXMF提供哪些产品和服务？

Manufactures oesophageal doppler haemodynamic monitoring systems.
Markets TrueVue monitoring systems globally.
Sells esophageal Doppler Probes for real-time blood flow measurement.
Offers Loops for aortic blood flow and blood pressure monitoring.
Provides High Definition Impedance Cardiography for non-invasive cardiac monitoring.
Develops PressureWave algorithm for pulse pressure waveform analysis.
Supplies Deltex Medical Esophageal Doppler Simulator for training.

DTXMF如何赚钱？

Direct sales of TrueVue haemodynamic monitoring systems.
Recurring revenue from the sale of disposable esophageal Doppler Probes.
Service and maintenance contracts for installed monitoring systems.
Training and education programs for clinicians on the use of their products.

Hospitals and surgical centers.
Critical care units.
Anesthesiologists and surgeons.
Medical professionals involved in fluid management during surgery and critical care.

Proprietary oesophageal Doppler technology.
Established brand reputation in haemodynamic monitoring.
Specialized product portfolio focused on fluid management.
Global distribution network.

什么因素可能推动DTXMF股价上涨？

Ongoing: Expansion of TrueVue adoption in US hospitals and surgical centers.
Ongoing: Strategic partnerships with medical device distributors.
Ongoing: Development of new haemodynamic monitoring technologies.
Ongoing: Integration of TrueVue data with EHR systems.

DTXMF的主要风险是什么？

Potential: Increased competition from established medical device companies.
Potential: Technological obsolescence of TrueVue technology.
Potential: Regulatory changes affecting medical device approvals.
Potential: Economic downturns impacting hospital budgets.
Ongoing: Negative profit margin and profitability challenges.

DTXMF的核心优势是什么？

Proprietary TrueVue oesophageal Doppler technology.
Established presence in key markets (UK, US, Spain, Canada).
Specialized product portfolio focused on haemodynamic monitoring.
High gross margin (63.3%) indicates pricing power.

DTXMF的劣势是什么？

Negative profit margin (-72.2%) indicates profitability challenges.
Small employee base (24) may limit scalability.
Reliance on a single product line (TrueVue).
OTC market listing may limit investor access.

DTXMF有哪些机遇？

Expansion in the US market.
Strategic partnerships and acquisitions.
Product innovation and development.
Adoption in emerging markets.

DTXMF面临哪些威胁？

Competition from established medical device companies.
Technological obsolescence.
Regulatory changes.
Economic downturns affecting hospital budgets.

DTXMF的竞争对手是谁？

Accuray Incorporated — Offers radiation therapy solutions. — (ACRDF)
Bellerophon Therapeutics Inc — Develops therapies for cardiopulmonary diseases. — (BLMHF)
Second Sight Medical Products Inc — Focuses on visual prosthetics. — (DOCRF)
Fluidigm Corporation — Provides microfluidics-based analytical tools. — (FFLWF)
Proximus NV — Telecommunications and ICT company. — (PXMVF)

Key Metrics

MoonshotScore: 51/100

Company Profile

CEO: Natalie Emilia Wettler
Headquarters: Chichester, GB
Employees: 24
Founded: 2009

AI Insight

AI analysis pending for DTXMF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Deltex Medical Group plc do?

Deltex Medical Group plc specializes in haemodynamic monitoring solutions, primarily through its TrueVue system. This system utilizes oesophageal Doppler technology to measure a patient's central vascular blood flow and fluid status in real-time. The company's products are used in various surgical and critical care settings to optimize fluid management, improve patient outcomes, and reduce complications related to fluid imbalances. Deltex Medical operates in the global medical devices market, with a focus on precision fluid management.

What do analysts say about DTXMF stock?

As of 2026-03-16, there is no available analyst consensus on DTXMF stock. Key valuation metrics include a negative P/E ratio of -0.22 and a market capitalization of $0.18 billion. The company's gross margin of 63.3% suggests potential for profitability with increased sales and cost management. Growth considerations include expanding adoption of TrueVue in the US market and potential partnerships with larger medical device companies. Investors should conduct their own due diligence before making any investment decisions.

What are the main risks for DTXMF?

Deltex Medical Group plc faces several risks, including competition from established medical device companies, the potential for technological obsolescence of its TrueVue technology, and regulatory changes affecting medical device approvals. The company's negative profit margin and profitability challenges also pose a significant risk. Additionally, economic downturns could impact hospital budgets and reduce demand for its products. As an OTC-listed company, DTXMF faces additional risks related to liquidity and transparency.